

United Therapeutics

[View the current United Therapeutics Page on BioPortfolio.com](http://www.bioportfolio.com/biorporate/10477-United+Therapeutics.html)

(<http://www.bioportfolio.com/biorporate/10477-United+Therapeutics.html>)

Contact Details:

1110 Spring Street

Silver Spring

MD

20910

United States of America

Tel: 301 608 9292

Fax: 301.608.9291

Email: webmaster@unither.com

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases. In these segments, United Therapeutics is actively developing four technology platforms: Prostacyclin Analogs, Immunotherapeutic Monoclonal Antibodies, Glycobiology, and Telemedicine. At United Therapeutics, we find tremendous inspiration for our work and view our products as being new beginnings for patients and doctors, with quality of life as our utmost therapeutic goal. The theme of United Therapeutics is "Medicines for Life" because all of our therapeutics address life-threatening illnesses.

Recent Publications by United Therapeutics:



- [Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion.](#)

This study assessed the relationship between dose and plasma concentration... 19th April, 2008
Clinical Affairs, United Therapeutics Corporation, One Park Drive, 4th- J Clin Pharmacol. 2008
Jan;48(1):19-25. ([DOI Direct Link](#))

- [Treprostinil for the treatment of pulmonary arterial hypertension in patients with New York Heart Association class II-IV symptoms.](#)

This study assessed the relationship between dose and plasma concentration... 9th December, 2006
United Therapeutics Corporation, Research Triangle Park, North Carolina- Pharmacotherapy. 2006
Aug;26(8):1203; discussion 1203-4. ([DOI Direct Link](#))

- [Pharmacokinetics and steady-state bioequivalence of treprostinil sodium \(Remodulin\) administered by the intravenous and subcutaneous route to normal volunteers.](#)

Treprostinil sodium is a chemically stable analogue of prostacyclin... 29th April, 2005
United Therapeutics Corporation, Research Triangle Park, North Carolina- J Cardiovasc Pharmacol.

2004 Aug;44(2):209-14.

- [Pulmonary hypertension.](#)

*Pulmonary hypertension, in its simplest sense, is elevation of the...*26th February, 2005

- Curr Probl Cardiol. 2004 Oct;29(10):575-634. ([DOI Direct Link](#))

- [Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.](#)

*The objective of this study was to assess the pharmacokinetics and safety...*17th December, 2004

United Therapeutics Corporation, One Park Drive, P.O. Box 14186, Research- J Clin Pharmacol. 2004 May;44(5):503-9. ([DOI Direct Link](#))

- [Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.](#)

*The objective of this study was to evaluate the absolute bioavailability...*13th May, 2004

United Therapeutics Corporation, Research Triangle Park, NC 27709, USA.- J Clin Pharmacol. 2004 Jan;44(1):83-8. ([DOI Direct Link](#))

- [Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin.](#)

*Treprostinil sodium was recently approved in the United States for...*13th April, 2004

United Therapeutics Corporation, Research Triangle Park, North Carolina- J Cardiovasc Pharmacol. 2003 Jun;41(6):908-15.

- [Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents.](#)

*The stability of treprostinil sodium after dilution in three common i.v....*5th September, 2003

United Therapeutics Corporation, 68 T. W. Alexander Drive, Research- Am J Health Syst Pharm. 2003 May 1;60(9):916-22.

Press Releases on United Therapeutics:

New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity	25th November, 2009	Hologic, Inc.	<i>BEDFORD, Mass., Nov. 25 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems</i>
SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors	25th November, 2009	SCAN Health Plan	<i>LONG BEACH, Calif., Nov. 25 /PRNewswire/ -- Thanksgiving meals will be delivered to approximately 1,000 homebound seniors in the greater Long Beach area thanks to Faith In Action/Volunteer Action for</i>
Heska Announces Supply Agreement With Roche Diagnostics	25th November, 2009	Heska Corporation	<i>LOVELAND, Colo., Nov. 25 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq: HSKA); ("Heska"), a leading provider of advanced diagnostic and specialty products to the veterinary industry,</i>

[Kansas City Prepares for Largest Free Health Clinic](#)

25th November, 2009

National Association of Free Clinics

KANSAS CITY, Mo., Nov. 25 /PRNewswire/ -- The Bartle Hall Convention Center will temporarily become the nation's largest medical clinic on Dec. 9-10, when Kansas City hosts the latest in a series

[MRS Leads the Mammography Industry in High Risk Alerts](#)

25th November, 2009

Mammography Reporting System, Inc. (MRS)

SEATTLE, Nov. 25 /PRNewswire/ -- Mammography Reporting System, Inc. (MRS) will demonstrate their newest high risk indicator at RSNA 2009, in Chicago. MRS is the only company in the industry offering

BioNews Results for United Therapeutics



- [Cell Therapeutics Wins Federal Appeal to Pursue \\$22.8 Million Claim Against The Lash Group](#)
PR Newswire: Nov 23 2009 12:48AM Matching: united therapeutics
- [Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leu](#)
PR Newswire: Nov 23 2009 12:48AM Matching: united therapeutics
- [FDA Approval for Uveitis Treatment for Sirion's Durezol](#)
Review of Ophthalmology: Nov 23 2009 12:39AM Matching: united therapeutics
- [Cornerstone Therapeutics Appoints General Counsel](#)
Pharma Live: Nov 22 2009 3:01PM Matching: united therapeutics
- [Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of ...](#)
PipelineReview: Nov 22 2009 12:12AM Matching: united therapeutics
- [Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal](#)
Freshnews.com: Nov 21 2009 12:41AM Matching: united therapeutics
- [iCo Therapeutics Completes Final Tranche of \\$4,000,000 Brokered Private Placement](#)
TickerTech.com: Nov 21 2009 8:42PM Matching: united therapeutics
- [iCo Therapeutics Completes Final Tranche of \\$4,000,000 Brokered Private Placement](#)
Yahoo! Canada: Nov 21 2009 4:40AM Matching: united therapeutics
- [Cell Therapeutics Wins Federal Appeal to Pursue \\$22.8 Million Claim Against The Lash Group](#)
KSLA: Nov 20 2009 4:37PM Matching: united therapeutics
- [Cell Therapeutics Wins Federal Appeal to Pursue \\$22.8 Million Claim Against The Lash Group](#)
KOTA Territory News: Nov 20 2009 10:38AM Matching: united therapeutics
- [Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal](#)
Pharma Live: Nov 20 2009 10:12PM Matching: united therapeutics
- [Cell Therapeutics Wins Federal Appeal to Pursue \\$22.8 Million Claim Against The Lash Group](#)
TickerTech.com: Nov 20 2009 9:33AM Matching: united therapeutics
- [Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leu](#)
KSLA: Nov 20 2009 4:35PM Matching: united therapeutics
- [Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of](#)

[Acute Myeloid Leu](#)

Montana's News Station: Nov 20 2009 11:36AM Matching: united therapeutics

- [Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leu](#)

KOTA Territory News: Nov 20 2009 10:37AM Matching: united therapeutics

United Therapeutics Clinical Trials:



- [Effect of Food on the Pharmacokinetics of Oral Treprostinil](#)

United Therapeutics Patents:



- 7596405- [Atrial fibrillation detection](#)
- 6441245- [Process for stereoselective synthesis of prostacyclin derivatives](#)
- 6521212- [Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation](#)
- 6528688- [Prostacyclin derivatives](#)
- 6700025- [Process for stereoselective synthesis of prostacyclin derivatives](#)
- 6756033- [Method for delivering benzindene prostaglandins by inhalation](#)
- 6803386- [Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer](#)
- 6809223- [Process for stereoselective synthesis of prostacyclin derivatives](#)
- 7199157- [Use of treprostinil to improve kidney functions](#)
- 7384978- [Compounds and methods for delivery of prostacyclin analogs](#)
- 7417070- [Compounds and methods for delivery of prostacyclin analogs](#)
- 7544713- [Compounds and methods for delivery of prostacyclin analogs](#)
- 6242482- [Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core

information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

